[1]
|
Nalysnyk, L., Rotella, P., Simeone, J.C., et al. (2017) Gaucher Disease Epidemiology and Natural History: A Comprehensive Review of the Literature. Hematology, 22, 65-73. https://doi.org/10.1080/10245332.2016.1240391
|
[2]
|
Zion, Y.C., Pappadopulos, E., Wajnrajch, M., et al. (2016) Re-Thinking Fatigue in Gaucher Disease. Orphanet Journal of Rare Diseases, 29, 1-7.
|
[3]
|
Masi, L. and Brandi, M.L. (2015) Gaucher Disease: The Role of the Specialist on Metabolic Bone Diseases. Clinical Cases in Mineral and Bone Metabolism, 12, 165-169. https://doi.org/10.11138/ccmbm/2015.12.2.165
|
[4]
|
Yang, A.C., Bier, L., Overbey, J.R., et al. (2017) Early Manifestations of Type 1 Gaucher Disease in Presymptomatic Children Diagnosed after Parental Carrier Screening. Genetics in Medicine, 19, 652-658.
https://doi.org/10.1038/gim.2016.159
|
[5]
|
Hughes, D., Mikosch, P., Belmatoug, N., et al. (2019) Gaucher Disease in Bone: From Pathophysiology to Practice. Journal of Bone and Mineral Research, 34, 996-1013. https://doi.org/10.1002/jbmr.3734
|
[6]
|
Casirati, G., Baldini, M., Ulivieri, F.M., et al. (2018) Skeletal Involvement in Type 1 Gaucher Disease: Not Just Bone Mineral Density. Blood Cells, Molecules and Diseases, 68, 148-152. https://doi.org/10.1016/j.bcmd.2017.06.003
|
[7]
|
Marcucci, G., Zimran, A., Bembi, B., et al. (2014) Gaucher Disease and Bone Manifestations. Calcified Tissue International, 95, 477. https://doi.org/10.1007/s00223-014-9923-y
|
[8]
|
Biegstraaten, M., Cox, T.M., Belmatoug, N., et al. (2016) Management Goals for Type 1 Gaucher Disease: An Expert Consensus Document from the European Working Group on Gaucher Disease. Blood Cells, Molecules and Diseases, 68, 203-208. https://doi.org/10.1016/j.bcmd.2016.10.008
|
[9]
|
Masi, L. and Brandi, M.L. (2015) Gaucher Disease: The Role of the Specialist on Metabolic Bone Diseases. Clinical Cases in Mineral and Bone Metabolism, 12, 165-169. https://doi.org/10.11138/ccmbm/2015.12.2.165
|
[10]
|
Kaluzna, M., Trzeciak, I., Ziemnicka, K., et al. (2019) Endocrine and Metabolic Disorders in Patients with Gaucher Disease Type 1: A Review. Orphanet Journal of Rare Diseases, 14, 275. https://doi.org/10.1186/s13023-019-1211-5
|
[11]
|
Clarke, L.A. and Hollak, C.E.M. (2015) The Clinical Spectrum and Pathophysiology of Skeletal Complications in Lysosomal Storage Disorders. Best Practice & Research Clinical Endocrinology & Metabolism, 29, 219-235.
https://doi.org/10.1016/j.beem.2014.08.010
|
[12]
|
Linaris (2015) Clinical Manifestations and Management of Gaucher Disease. Clinical Cases in Mineral and Bone Metabolism, 12, 157-164. https://doi.org/10.11138/ccmbm/2015.12.2.157
|
[13]
|
Revel-Vilk, S., Szer, J., Mehta, A., et al. (2018) How We Manage Gaucher Disease in the Era of Choices. British Journal of Haematology, 182, 467-480. https://doi.org/10.1111/bjh.15402
|
[14]
|
中华医学会儿科学分会遗传代谢内分泌学组, 中华医学会儿科学分会血液学组, 中华医学会血液学分会红细胞疾病(贫血)学组. 中国戈谢病诊治专家共识(2015) [J]. 中华儿科杂志, 2015, 53(4): 256-261.
|
[15]
|
El-Beshlawy, A., Tylki-Szymanska, A., Vellodi, A., et al. (2017) Long-Term Hematological, Visceral, and Growth Outcomes in Children with Gaucher Disease Type 3 Treated with Imiglucerase in the International Collaborative Gaucher Group Gaucher Registry. Molecular Genetics and Metabolism, 120, 47-56.
https://doi.org/10.1016/j.ymgme.2016.12.001
|
[16]
|
Murugesan, V., Chuang, W.L., Liu, J., et al. (2016) Glucosylsphingosine Is a Key Biomarker of Gaucher Disease. American Journal of Hematology, 91, 1082-1089. https://doi.org/10.1002/ajh.24491
|
[17]
|
Irún, P., Cebolla, J.J., López de Frutos, L., et al. (2020) LC-MS/MS Analysis of Plasma Glucosylsphingosine as a Biomarker for Diagnosis and Follow-Up Monitoring in Gaucher Disease in the Spanish Population. Clinical Chemistry and Laboratory Medicine, 58, 798-809. https://doi.org/10.1515/cclm-2019-0949
|
[18]
|
Rolfs, A., Giese, A.K., Grittner, U., et al. (2013) Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients. PLoS ONE, 8, e79732. https://doi.org/10.1371/journal.pone.0079732
|
[19]
|
Smid, B.E., Ferraz, M.J., Verhoek, M., et al. (2016) Biochemical Response to Substrate Reduction Therapy versus Enzyme Replacement Therapy in Gaucher Disease Type 1 Patients. Orphanet Journal of Rare Diseases, 11, 28.
https://doi.org/10.1186/s13023-016-0413-3
|
[20]
|
Tylki-Szymańska, A., Szymańska-Rożek, P., Hasiński, P., et al. (2018) Plasma Chitotriosidase Activity versus Plasma Glucosylsphingosine in Wide Spectrum of Gaucher Disease Phenotypes—A Statistical Insight. Molecular Genetics and Metabolism, 123, 495-500. https://doi.org/10.1016/j.ymgme.2018.02.004
|